Invivyd, Inc. · NASDAQ:IVVD
Invivyd — TD Cowen 43rd Annual Health Care Conference (March 2023)
14 slides from Invivyd's conference presentation, Mar 6, 2023
Slide 1: TD Cowen 43rd Annual Health Care Conference
Exhibit 99.2 TD Cowen 43rd Annual Health Care Conference March 6, 2023
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Our Vision & Purpose
OUR VISION & PURPOSE Providing Hope for Vulnerable People Against Viral Diseases Our purpose is to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2 3
Slide 4: COVID Is Third Leading Cause of Death in the U.S.
COVID IS THIRD LEADING CAUSE OF 1 DEATH IN THE U.S. Vaccination and increased levels of population immunity have reduced SARS-CoV-2 associated diseases and mortality; however, significant unmet medical need remains Immunocompromised people are No vaccine alternatives for People at higher risk of Und
Slide 5: Invivyd: A Platform Approach to Innovation
INVIVYD: A PLATFORM APPROACH TO INNOVATION OUR DISCOVERY APPLICATION IN VIRAL PIPELINE FOCUS PLATFORM DISEASES • Growing number of • VYD222: a monoclonal • Antibodies designed to • Rapid repeated antibody antibodies aiming to antibody for prevention or protect humanity from serious isolation, engine
Slide 6: Approach to Selection of Next Generation COVID-19 Product Candidates
INVIVYD IN ACTION: APPROACH TO SELECTION OF NEXT GENERATION COVID-19 PRODUCT CANDIDATES Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat ~10 million B Cells MINE Mine human antibody repertoires induced following
Slide 7: Showcase of VYD222: Engineered for Broad Activity and Prolonged Utility
SHOWCASE OF VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY VYD222 (Engineered from adintrevimab) Designed for: • High potency • Lack of polyreactivity VYD222 • Long half-life • Developability • Potential to resist escape • Target non-overlapping epitopes of spike RBD • Rare epitopes und
Slide 8: VYD222 Demonstrated Broad In Vitro Neutralizing Activity Against Variants
VYD222 DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIANTS OF CONCERN AND SUB-LINEAGES ®* * VARIANT SUBLINEAGE VYD222 EVUSHELD BEBTELOVIMAB WT(D614G) WT(D614G)✓ ✓✓ Delta B.1.617.2✓ ✓✓ BA.1✓ ✓ - BA.4/5✓ ✓✓ BA.4.6✓ ✓ X BF.7 - ✓ - BQ.1.1 X ✓ X BA.2.75✓ ✓ - XBB.1 X ✓ X X XBB.1.5 ✓ X ✓ Neu
Slide 9: Development Success and Speed with Adintrevimab: IND to Topline in 16 Months
DEMONSTRATED DEVELOPMENT SUCCESS AND SPEED WITH ADINTREVIMAB: FROM IND TO TOPLINE DATA IN 16 MONTHS Late Q4 2020 1H 2021 2H 2021 Q1 2022 Adintrevimab IND Phase 1 First in EVADE STAMP (treatment) Adintrevimab st Enabling & Human 1 Subject (prevention) Ph2/3 Enrollment Topline Data Submission Dosed Ph
Slide 10: Regulators Considering Strategies to Accelerate Monoclonal Antibody Development
REGULATORS CONSIDERING STRATEGIES TO ACCELERTATE MONOCLONAL ANTIBODY DEVELOPMENT TIMELINES • Regulators are seeking strategies to streamline development of monoclonal antibodies and vaccines • The necessity of streamlined development for new mAb products is supported by the science • Understanding o
Slide 11: Building on Our Vision to Create the Perpetual Machine
BUILDING ON OUR VISION TO CREATE THE “PERPETUAL MACHINE” PREDICTION of viral evolution and rational selection of privileged epitopes Candidate antibody DISCOVERY and ENGINEERING COMMERCIAL design for a large drug category, not solely a pandemic emergency Efficient clinical DEVELOPMENT for multiple u
Slide 12: VYD222 Is One of Many Antibodies in Invivyd's Pipeline
VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD’S ROBUST PIPELINE DEVELOPMENT STATUS PROGRAMS PLATFORM INDICATION(S) STATUS DISCOVERY IND-ENABLING PHASE 1 PHASE 2 PHASE 3 CORONAVIRUSES Ph 1 trial planned Prevention or VYD222 mAb for Q1 2023 Treatment Engineering Prevention or VYD224 mAb variant matching
Slide 13: Company Well Capitalized to Develop Lead Candidate & Additional Pipeline Assets
COMPANY WELL CAPITALIZED TO DEVELOP LEAD CANDIDATE & ADDITIONAL PIPELINE ASSETS Total fully diluted shares of Cash Position: common stock Cash, cash equivalents and Planned cash runway into outstanding* as of marketable securities were Q2 2024 $419 million as of September September 30, 2022: 30, 202
Slide 14: Thank You
_ INVIVYD Ly THANK YOU
Invivyd — TD Cowen 43rd Annual Health Care Conference (March 2023) on 6ix